The Center for Medicare and Medicaid Services stated in a press release on Friday that the monthly premiums for medical insurance members’ doctors and outpatient services will increase by nearly 15% in 2022.
The agency attributed the increase to rising health care prices driven by COVID-19-related care, legislators’ initiatives to reduce 2021 premiums during the pandemic, and the potential for expensive drugs such as Biogen Aduheim Accept the report.
In 2022, the standard monthly premium will rise to US$170.10, an increase of 14.5% from this year’s US$148.50. The annual deductible will increase by US$233, an increase of 14.7% from the US$203 in 2021. Participants will receive a 5.9% year-on-year cost of living adjustment through Social Security benefits, which will exceed the increase in Medicare Part B monthly premiums, the agency said. CMS said this was the largest increase in the cost of living in 30 years.
Medical insurance premiums for inpatient care in hospitals will also rise in 2022, but CMS points out that approximately 99% of beneficiaries will not pay premiums for these services. Nevertheless, if admitted in 2022, those who need to bear the expenses will pay a deductible of $1,556, an increase of $72 from the $1,484 in 2021. The daily co-insurance rate for beneficiaries’ inpatient care from day 61 to day 90, lifetime reserve in 2022, and the number of occupants in skilled nursing institutions will also increase.
CMS administrator Chiquita Brooks-LaSure said in a statement: “CMS is committed to ensuring that people who rely on Medicare today are provided with high-quality care and affordable insurance, while protecting the sustainability of Medicare for future generations.” Press Releases“The increase in Part B premiums in 2022 continues to prove that rising drug costs threaten the affordability and sustainability of medical insurance plans.”
Based on their income, the monthly premiums for beneficiaries with Medicare drug coverage range from $0 to $77.90.
Legislators have focused on solving the problem of prescription drug costs in the “Rebuild Better Act.”Representative Frank Palon (DN.J.), chairman of the Energy and Commerce Committee, said that rising medical insurance premiums emphasize the need for Congress Let Medicare negotiate these prices.
Palon said at the press conference: “The soaring drug prices not only make it more difficult for the elderly to afford the life-saving drugs they need, but it also pushes up the cost of medical care and outpatient care.”
A poll conducted by the Caesars Family Foundation in June showed that nearly 90% of consumers believe that the federal government should negotiate directly with drug manufacturers to keep prices down. Respondents in the political field agreed that reducing prescription costs should be a key priority for President Joe Biden’s administration.
In June, the Food and Drug Administration Approved the intravenous drug aducanumab for US$56,000, Sold under the name of Aduhelm, contrary to the advice of the FDA consultant that the agency rejected the application of the drug manufacturer Biogen.
It is expected that the new Alzheimer’s treatment will include More than 1% According to a report released earlier this year by the non-profit research organization Altarum, by the mid-2020s, all countries’ health expenditures will account for half of the country. The drug will increase non-retail drug expenditures (treatment in hospitals or clinics) by at least 25%. According to the report, spending on prescription drugs in the United States will increase by at least 8% in the next few years.
At least six Blue Cross Blue Shield affiliates have decided not to underwrite Aduhelm. For-profit insurance companies such as UnitedHealth Group said they are waiting for underwriting decisions based on federal government initiatives.The Mount Sinai Health System and the Cleveland Clinic stated that they Can’t prescribe medicine, The reason is that it does not work.